Working… Menu

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01494662
Recruitment Status : Recruiting
First Posted : December 19, 2011
Last Update Posted : April 2, 2021
Translational Breast Cancer Research Consortium
Puma Biotechnology, Inc.
Information provided by (Responsible Party):
Rachel Freedman, MD, MPH, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023
Publications automatically indexed to this study by Identifier (NCT Number):